NCT02221414View on ClinicalTrials.gov

Bioequivalence of a 2.5 mg Linagliptin / 500 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 500 mg Tablets Administered Together in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

March 31, 2010

Conditions
Healthy
Interventions
DRUG

Linagliptin/Metformin FDC

DRUG

Linagliptin

DRUG

Metformin

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY